Progression-Free Survival as Early Efficacy Endpoint in Resectable Esophageal Cancer Treated With Neoadjuvant Therapy: A Systematic Review

To investigate literature-based evidence regarding progression-free survival (PFS) as an early efficacy endpoint in patients with resectable esophageal or gastroesophageal junction (GEJ) cancer receiving neoadjuvant therapy, this study identified large-scale randomized controlled trials (RCTs) with...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jie, Tao, Jin, Dai, Zhen, Tan, Yan, Jiang, Li, Wang, Qifeng, Lang, Jinyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801608/
https://www.ncbi.nlm.nih.gov/pubmed/35111667
http://dx.doi.org/10.3389/fonc.2021.771546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801608/
https://www.ncbi.nlm.nih.gov/pubmed/35111667
http://dx.doi.org/10.3389/fonc.2021.771546

Ejemplares similares